Inspire Medical Systems (NYSE:INSP) Reports Q3 2025 Financial Results, Reaffirms Guidance

November 3, 2025 — Inspire Medical Systems, Inc. (NYSE: INSP) today released its financial results for the third quarter ended September 30, 2025. The company reported revenue of $224.5 million, a 10% increase from the same quarter last year, and a gross margin of 85.8%. Net income was $9.9 million, or $0.34 per share, while adjusted net income was $11.2 million, or $0.38 per share.

Operating cash flow reached $68.5 million for the quarter, bringing the year-to-date total to $64.5 million. The company completed $50 million in share repurchases and presented Inspire V safety and efficacy data at recent industry meetings. Full-year revenue guidance is reaffirmed at $900 to $910 million, and diluted net income per share guidance is increased to $0.90 to $1.00.

“The Inspire team had a very productive third quarter focusing on the transition to the Inspire V system while delivering very strong results globally,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems.

Investor & Media Contact:
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

Source: Inspire Medical Systems

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.